Loading clinical trials...
Loading clinical trials...
Dexamethasone-sparing Based on Netupitant/Palonosetron(NEPA) With Olanzapine for the Effect of Chemotherapy-induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: a Randomized Noninferiority III Phase Trial
Conditions
Interventions
Netupitant / Palonosetron Oral Capsule [Akynzeo]
Olanzapine
+1 more
Locations
1
China
Fudan University Shanghai Cancer Cancer
Shanghai, Shanghai Municipality, China
Start Date
May 1, 2024
Primary Completion Date
August 1, 2025
Completion Date
August 30, 2025
Last Updated
April 9, 2026
NCT05838638
NCT02106494
NCT04054193
NCT05841849
NCT01937156
NCT04437017
Lead Sponsor
Fudan University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions